Tenaya Therapeutics, Inc. (TNYA)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
0.78 USD
+0.04
(4.685%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 0.78 -0.01 (-0.006%) ⇩ (April 17, 2026, 7:57 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 2:49 p.m. EDT
Tenaya Therapeutics (TNYA) presents a high-risk, high-reward scenario. Despite positive news about its product pipeline and collaborations, the stock has shown significant volatility and negative fundamentals. The recent price action indicates a lack of consistent momentum, and the low dividend yield makes it unattractive for income-focused investors. Short-term traders might consider the stock for potential momentum plays, but the overall outlook is bearish, and long-term investors should be cautious. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.122322 |
| AutoETS | 0.122877 |
| AutoARIMA | 0.122877 |
| AutoTheta | 0.399283 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.17 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.408 |
| Excess Kurtosis | -0.98 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 8.786 |
| Market Cap | 169,714,832 |
| Forward P/E | -1.73 |
| Beta | 3.00 |
| Website | https://www.tenayatherapeutics.com |
As of April 11, 2026, 2:49 p.m. EDT: Options speculators are showing mixed signals. Call options, particularly those with strikes at $1.0 and $1.5, have significant open interest and volume, suggesting some bullish sentiment. However, put options, especially those at $1.0 and $1.5, also show high open interest, indicating potential bearish sentiment. The overall volatility is low, but the presence of high open interest in both calls and puts suggests uncertainty about the stock's future direction.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.63100433 |
| Address1 | 171 Oyster Point Boulevard |
| Address2 | Suite 500 |
| All Time High | 32.0 |
| All Time Low | 0.36 |
| Ask | 0.8069 |
| Ask Size | 8 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 2,935,570 |
| Average Daily Volume3 Month | 4,398,513 |
| Average Volume | 4,398,513 |
| Average Volume10Days | 2,935,570 |
| Beta | 2.995 |
| Bid | 0.7522 |
| Bid Size | 14 |
| Book Value | 0.569 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.7821 |
| Current Ratio | 6.84 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.814 |
| Day Low | 0.76 |
| Debt To Equity | 8.786 |
| Display Name | Tenaya Therapeutics |
| Earnings Timestamp | 1,773,259,200 |
| Earnings Timestamp End | 1,778,702,400 |
| Earnings Timestamp Start | 1,778,702,400 |
| Ebitda | -84,895,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.942 |
| Enterprise Value | 79,997,824 |
| Eps Current Year | -0.42875 |
| Eps Forward | -0.452 |
| Eps Trailing Twelve Months | -0.59 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.72476 |
| Fifty Day Average Change | 0.057340026 |
| Fifty Day Average Change Percent | 0.07911588 |
| Fifty Two Week Change Percent | 63.100433 |
| Fifty Two Week High | 2.35 |
| Fifty Two Week High Change | -1.5679 |
| Fifty Two Week High Change Percent | -0.6671915 |
| Fifty Two Week Low | 0.36 |
| Fifty Two Week Low Change | 0.4221 |
| Fifty Two Week Low Change Percent | 1.1725 |
| Fifty Two Week Range | 0.36 - 2.35 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,651,800,000 |
| Float Shares | 166,770,146 |
| Forward Eps | -0.452 |
| Forward P E | -1.7303098 |
| Free Cashflow | -37,358,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 70 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00537 |
| Held Percent Institutions | 0.50298 |
| Implied Shares Outstanding | 216,998,877 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. |
| Long Name | Tenaya Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 169,714,832 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_409125654 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -90,597,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 170,018,619 |
| Number Of Analyst Opinions | 7 |
| Open | 0.7625 |
| Operating Cashflow | -68,264,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 650 825 6990 |
| Post Market Change | -0.0062000155 |
| Post Market Change Percent | -0.79273945 |
| Post Market Price | 0.7759 |
| Post Market Time | 1,776,470,235 |
| Previous Close | 0.7471 |
| Price Eps Current Year | -1.82414 |
| Price Hint | 4 |
| Price To Book | 1.3745167 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.514 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | 0.035 |
| Regular Market Change Percent | 4.68478 |
| Regular Market Day High | 0.814 |
| Regular Market Day Low | 0.76 |
| Regular Market Day Range | 0.76 - 0.814 |
| Regular Market Open | 0.7625 |
| Regular Market Previous Close | 0.7471 |
| Regular Market Price | 0.7821 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 3,284,123 |
| Return On Assets | -0.43717 |
| Return On Equity | -0.83839995 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 216,998,876 |
| Shares Percent Shares Out | 0.1161 |
| Shares Short | 25,187,788 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 23,550,941 |
| Short Name | Tenaya Therapeutics, Inc. |
| Short Percent Of Float | 0.22219999 |
| Short Ratio | 4.5 |
| Source Interval | 15 |
| State | CA |
| Symbol | TNYA |
| Target High Price | 40.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 9.0 |
| Target Median Price | 3.0 |
| Total Cash | 100,547,000 |
| Total Cash Per Share | 0.463 |
| Total Debt | 10,830,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.59 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.021765 |
| Two Hundred Day Average Change | -0.23966497 |
| Two Hundred Day Average Change Percent | -0.23455977 |
| Type Disp | Equity |
| Volume | 3,284,123 |
| Website | https://www.tenayatherapeutics.com |
| Zip | 94,080 |